West Pharmaceutical Services (WST) Total Current Liabilities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Total Current Liabilities for 18 consecutive years, with $640.5 million the latest figure, recorded in Q2 2026.

• Quarterly Total Current Liabilities rose 5.94% year-over-year to $640.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $640.5 million (up 5.94% YoY) and the FY2025 annual result came in at $654.9 million, up 18.99% from the prior year.
• Total Current Liabilities fell to $640.5 million in Q2 2026 per WST's latest filing, from $674.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for WST reached as high as $674.0 million in Q1 2026 and fell as low as $456.7 million in Q3 2022.
• A 5-year average of $581.2 million and a median of $574.9 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities gained 29.44% — and 2025, when it retreated 18.77%.
• Year by year, Total Current Liabilities stood at $519.0 million in 2022, then advanced by 29.44% to $671.8 million in 2023, then declined by 18.07% to $550.4 million in 2024, then advanced by 18.99% to $654.9 million in 2025, then slipped by 2.2% to $640.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $640.5 million, $674.0 million, and $654.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.